PCR Markets for Life Sciences Applications (Market by Type – qPCR, dPCR – Application – Pharmaceutical, General Research, and by Country and Region)
As part of its coverage of this market, Kalorama Information’s report provides:
- The Market for Life Sciences PCR, 2017 to 2022
- Application Market Segmentation of Pharmaceutical and General Medical Research
- Market Segmentation of qPCR and dPCR markets, 2017-2022
- United States Life Sciences PCR Market, 2017-2022
- European Life Sciences PCR Market, 2017-2022
- Japanese Market for Life Sciences PCR, 2017-2022
- China Market for Life Sciences PCR, 2017-2022
- LATAM Market for Life Sciences PCR, 2017-2022
- Rest of World Market for Life Sciences PCR, 2017-2022
The life science market for PCR grew steadily for over two decades, although this growth is leveling off now. This is a large, diverse market that is now facing competition from next generation sequencing for a number of applications.
PCR technology has been widely licensed to other companies for both life science (for the purposes of this report, the research market equals the life science market) and diagnostic applications, and many companies are now active in these fields. Real-time PCR (qPCR) has become the most widely used DNA amplification method today.
PCR was the first of what are now many nucleic acid amplification test (PCR) methods that have been developed and commercialized. Examples of isothermal PCRs include loop mediated isothermal amplification (LAMP), nicking enzyme amplification reaction (NEAR), strand displacement amplification (SDA), nucleic acid sequence based amplification (NASBA) and transcription-mediated amplification (TMA).
Isothermal PCRs have been developed that can provide results more quickly than qPCR, sometimes in less than 30 minutes. Reduced equipment requirements, simpler workflows and applicability to sample-to-answer platforms make isothermal methods ideal for decentralized and point-of-care molecular diagnostics. Both isothermal PCR and qPCR technologies are being applied to point-of-care and near-patient molecular diagnostics, opening up another new market for PCR-based tests.
Over time, many changes and improvements in PCR technology have been developed. One significant advance was the development of real-time PCR. With real-time PCR, detection of the amplicon occurs in real-time as the amplification reaction progresses, versus the initial PCR test technology method (traditional PCR), in which detection of amplified DNA product (amplicon) takes place at the end of the reaction (end-point PCR). Real-time PCR assays can be quantitative assays, measuring the initial number of copies of the target or template DNA that is present in a sample. Real-time PCR is typically referred to as qPCR, while the term “”RT-PCR”” is usually reserved for reverse transcriptase PCR, a method used to make a complementary DNA (cDNA) strand from RNA.
Digital PCR (dPCR) divides the reaction into smaller, discrete reactions, partitioning them so that individual nucleic acid molecules are localized and concentrated within numerous separate regions, be they in microplates, capillaries, arrays of miniaturized chambers, or water-oil emulsions (in a technique called droplet digital PCR, or ddPCR).
This report breaks out markets by both types of PCR.